Low dose of homoharringtonine and cytarabine-based priming induction regimens for patients with de novo acute myeloid leukemia and high-risk myelodysplastic syndrome aged over 70 years

Fang WangDepartment of Hematology/Oncology, First Hospital of Tsinghua University, Beijing, People’s Republic of ChinaView further author information

Wenyan XuDepartment of Hematology/Oncology, First Hospital of Tsinghua University, Beijing, People’s Republic of ChinaView further author information

Li LiuDepartment of Hematology/Oncology, First Hospital of Tsinghua University, Beijing, People’s Republic of ChinaView further author information

Xiuhong RenDepartment of Hematology/Oncology, First Hospital of Tsinghua University, Beijing, People’s Republic of ChinaView further author information

Pingping LiuDepartment of Hematology/Oncology, First Hospital of Tsinghua University, Beijing, People’s Republic of ChinaView further author information

Li ZhengDepartment of Hematology/Oncology, First Hospital of Tsinghua University, Beijing, People’s Republic of ChinaView further author information

Hao ZhangDepartment of Hematology/Oncology, First Hospital of Tsinghua University, Beijing, People’s Republic of ChinaView further author information

Songsong ZhangDepartment of Hematology/Oncology, First Hospital of Tsinghua University, Beijing, People’s Republic of ChinaView further author information

Yaru XuDepartment of Hematology/Oncology, First Hospital of Tsinghua University, Beijing, People’s Republic of ChinaView further author information

Zhenxing GuoDepartment of Hematology/Oncology, First Hospital of Tsinghua University, Beijing, People’s Republic of ChinaCorrespondence[email protected]
View further author information

Articles from other publishers (1)